Status:
TERMINATED
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
Lead Sponsor:
Shradha Agarwal
Collaborating Sponsors:
Prometheus Laboratories
Conditions:
Crohn's Disease
Eligibility:
All Genders
7+ years
Phase:
NA
Brief Summary
The purpose of this study is to improve the investigators understanding of the relationship between Crohn's disease and blood levels of the drug infliximab (Remicade). The investigators want to determ...
Detailed Description
The efficacy of infliximab to maintain remission in Crohn's disease has been confirmed by randomized, controlled trials, however the utility of serum infliximab and ATI titers is less clearly describe...
Eligibility Criteria
Inclusion
- Patients with active (HBI \>10) refractory inflammatory and/or perianal fistulizing Crohn's disease who are prescribed infliximab as standard of care by their gastroenterologist.
Exclusion
- Pregnant women.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01438151
Start Date
December 1 2011
End Date
December 1 2013
Last Update
April 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029